Lidds AB (FRA:5LD) WACC %:8.74% (As of Jun. 28, 2026) — 31% Above Median


What is Lidds AB WACC %?

Lidds AB FRA:5LD WACC % is 8.74% as of Jun. 28, 2026, which is 31% above its 10-year median of 6.67. The stock has 2 warning signs investors should review.

As of today (2026-06-28), Lidds AB's weighted average cost of capital is 8.74%%. Lidds AB's ROIC % is -366.47% (calculated using TTM income statement data). Lidds AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.

For a comprehensive WACC calculation, please access the WACC Calculator.


Lidds AB  (FRA:5LD) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Lidds AB's weighted average cost of capital is 8.74%%. Lidds AB's ROIC % is -366.47% (calculated using TTM income statement data). Lidds AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

Lidds AB WACC % Historical Data

* Premium members only.

The historical data trend for Lidds AB's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lidds AB WACC % Chart

Lidds AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
WACC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.01 6.14 7.88 7.10 8.10

Lidds AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.93 8.10 8.60 8.31 8.56

FRA:5LD vs VRTX, REGN, ALNY: WACC % Comparison

For the Biotechnology subindustry, Lidds AB's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lidds AB WACC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lidds AB's WACC % distribution charts can be found below:

* The bar in red indicates where Lidds AB's WACC % falls into.



Lidds AB WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Lidds AB's market capitalization (E) is €0.315 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Sep. 2025, Lidds AB's latest one-year quarterly average Book Value of Debt (D) is €0 Mil.
a) weight of equity = E / (E + D) = 0.315 / (0.315 + 0) = 1
b) weight of debt = D / (E + D) = 0 / (0.315 + 0) = 0

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 2.7446%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Lidds AB's beta cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 2.7446% + 1 * 6% = 8.7446%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Sep. 2025, Lidds AB's interest expense (positive number) was €0.002 Mil. Its total Book Value of Debt (D) is €0 Mil.
Cost of Debt = 0.002 / 0 = %.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0 / -0.356 = 0%.

Lidds AB's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=1*8.7446%+0*%*(1 - 0%)
=8.74%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 8.74% mean?
Lidds AB (FRA:5LD) has a WACC % of 8.74% as of Jun. 28, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Lidds AB and its competitors. This is 31% above median its historical median of 6.67. Over the past decade, Lidds AB's WACC % has ranged from 6.01 to 8.74.
Is Lidds AB's WACC % too high?
Lidds AB's current WACC % of 8.74% is 31% above median its 10-year median of 6.67. Over the past 10 years, this metric has ranged from a low of 6.01 to a high of 8.74. The Biotechnology industry median WACC % is 9.99. Lidds AB's value of 8.74% is 12.5% below this industry median.
How does Lidds AB's WACC % compare to VRTX and REGN?
Lidds AB's WACC % of 8.74% can be compared against companies in the Biotechnology industry. The industry median WACC % is 9.99. Lidds AB's value of 8.74% is 12.5% below this benchmark. Historically, Lidds AB's own WACC % has ranged from 6.01 to 8.74 over the past decade. While the company's 10-year median is 6.67 vs. the industry median of 9.99, Lidds AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 9.99, based on 1,426 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lidds AB's current WACC % of 8.74% is 12.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Lidds AB and its competitors. For the Biotechnology industry, the median WACC % is 9.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lidds AB's current WACC % is 8.74%, which is 31% above median its own 10-year median of 6.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lidds AB stock overvalued right now?
Lidds AB (FRA:5LD) has a current WACC % of 8.74%. The current WACC % is 8.74%, which is 31% above median its 10-year median of 6.67 and 12.5% below the Biotechnology industry median of 9.99. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Lidds AB (FRA:5LD), the current WACC % is 8.74% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lidds AB Business Description

Address c/o Excore, Kungsportsavenyen 22, Goteborg, SWE, 411 36
Lidds AB is a Sweden-based drug delivery company focused on its proprietary NanoZolid technology platform. The NanoZolid system is used to formulate drugs for local administration with controlled and sustained release over extended periods. The company offers this technology to partners and is also developing its own pipeline of drug candidates, prominently in oncology, where the platform is used to enable localized and sustained drug delivery. It has a pipeline with several projects in clinical development, both in early- and late-stage clinical phases, and projects about to enter clinical development.